This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.

Coverage of stories discussed this week on ascopost.com:

Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex

FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

To listen to more podcasts from ASCO, visit asco.org/podcasts.